All posts

H2O Innovation gets new $4.00 target at Beacon Securities

Beacon Securities is staying bullish on water treatment solutions company H2O Innovation (H2O Innovation Stock Quote, Chart, News, Analysts, Financials TSXV:HEO). Analyst Gabriel Leung delivered a corporate update on Tuesday where he kept his “Buy” rating and increased his target price to $4.00 (was $3.00), saying the company’s new tuck-in acquisition is looking good.

Quebec City-based H2O Innovation designs, builds and operates custom, state-of-the-art integrated water treatment solutions based on membrane filtration technology for municipal and industrial clients, along with marketing a range of specialty chemicals for water treatment and conditioning. The company announced on Monday it has acquired the remaining 76 per cent of issued and outstanding shares of Madrid, Spain-based Genesys Membrane Products (GMP). H2O Innovation had previously taken a 24-per-cent ownership stake in the company through the acquisition in November 2019 of UK-based Genesys.

Starting out as a technical service partner for Genesys, GMP has developed specialized membrane autopsy capabilities and also sells specialty chemicals, filters and complementary products to the membrane industry. GMP’s revenue for 2020 was about $7.75 million, and 24 per cent of its EBITDA has already been accounted for in H2O’s numbers as a share of profit in an associate. H2O said with the close of the deal it will increase the company’s EBITDA on a proforma basis by more than ten per cent.

H2O president and CEO Frédéric Dugré said acquiring the whole of GMP is the next logical step for the company in becoming “the world’s largest membrane specialty chemicals and associated services supplier” sold through a large distribution network.

“GMP’s laboratory is globally recognized as the preeminent membrane autopsy facility in the industry and will support our Genesys and PWT teams in their sales efforts going forward. This laboratory has the experience and expertise of thousands of membrane autopsies performed over the years,” Dugré said in a press release.

H2O Innovation has seen its share price take off over the past few months. HEO doubled its value in 2020, finishing up 106 per cent, while so far in 2021 the stock is up a further 50 per cent.

Looking at the GMP deal, Leung said at about $7 million HEO paid 6x EBITDA for the 76-per-cent stake (H2O paid $2.4 million at the close of the acquisition with earnouts coming over three years based on GMP’s 2021 and 2022 EBITDA.

“GMP’s presence in Santiago, Chile, through its wholly owned subsidiary Genesys Membrane Products Latinoamerica Limitada, also positions HEO to better access the Latin American membrane chemical market, in particular the mining industry. GMP recently won a two-year contract for membrane cleaning chemicals and site services of approximately $3 million for a large mining customer in Chile,” Leung wrote.

“Bottom-line, we believe this transaction will be an accretive one for HEO, which enhances its technical expertise and also geographic footprint, particularly in Latin America,” he said.

On H2O, Leung said its strong organic growth prospects as shown from its performance during the pandemic and via strong macro tailwinds along with its healthy M&A pipeline and “impressive” operational performance have all contributed to his target raise, which at now 2x fiscal 2022 EV/Sales is in-line with its peer group.

“We believe the company continues to explore new opportunities in its O&M and Specialty divisions, which should further augment its recurring revenue base. With the company now operating at a net debt ratio of sub-1x and generating strong FCF, we also believe it is in good position to move forward with acquisitions with minimal dilution (depending in the size of the transaction),” Leung wrote.

Looking at H2O’s financials, Leung is calling for the company to generate fiscal 2021 (year end June 30) revenue and adjusted EBITDA of $147.7 million and $14.4 million, respectively, and fiscal 2022 revenue and adjusted EBITDA of $161.0 million and $17.3 million, respectively. At press time, the analyst’s new $4.00 target represented a projected one-year return of 31 per cent.

In early December, H2O announced a three-year strategic plan, aiming for between $175 and $250 million in revenues by the end of its fiscal 2023 with adjusted EBITDA margins reaching above 11 per cent. The company said its pipeline of acquisition targets is “rich in opportunities” and is diversified in terms of company size and profile, with H2O aiming to complete between two and four acquisitions over the next 30 months. The company said it intends to do its M&A without share dilution unless required for a significantly transaction in terms of size.

H2O said the global water market, currently at $842 billion, is expected to grow annually by between five and 14 per cent, with fundamental drivers coming in the form of population growth, tightening regulations, water scarcity and growing demand from agriculture and industry.

“To develop the three-year strategic plan, the Corporation’s executive team, in collaboration with the business line managers, has identified specific sub-markets and sub-segments to determine a current addressable market for H2O Innovation in the range of $4.5 billion. This addressable market is where the Corporation intends to continue its growth during the next three years, both organically and through mergers and acquisitions,” the company said in a December 8 press release.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: heo
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

20 hours ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

20 hours ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

21 hours ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

1 day ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

2 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

2 days ago